Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

(2010) Gionata Fiorino et al.   Expert Review of Clinical Immunology

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

(2010) Wendy S. Putnam et al.   TRENDS IN BIOTECHNOLOGY

A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis

(2009) Dan Turner et al.   Clinical Gastroenterology and Hepatology

Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together?

(2009) Y. Leung et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Biological Therapies for Inflammatory Bowel Diseases

(2009) Paul Rutgeerts et al.   GASTROENTEROLOGY

Immunotoxicity profile of natalizumab

(2009) Nancy G. Wehner et al.   Journal of Immunotoxicology

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

(2008) James D. Lewis et al.   INFLAMMATORY BOWEL DISEASES